Generic Name: trastuzumab
Common side effects of Herceptin include: febrile neutropenia, infection, asthenia, dizziness, fever, headache, nausea, pain, skin rash, vomiting, abdominal pain, back pain, diarrhea, flu-like symptoms, insomnia, neutropenia, pharyngitis, rhinitis, chills, and anorexia. Other side effects include: urinary tract infection, anemia, arthralgia, depression, edema, ostealgia, paresthesia, sinusitis, and tachycardia.  See below for a comprehensive list of adverse effects.
Applies to trastuzumab: intravenous powder for solution
In addition to its needed effects, some unwanted effects may be caused by trastuzumab (the active ingredient contained in Herceptin). In the event that any of these side effects do occur, they may require medical attention.

If any of the following side effects occur while taking trastuzumab, check with your doctor or nurse immediately:
Some of the side effects that can occur with trastuzumab may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:


Applies to trastuzumab: intravenous powder for injection
The most common adverse events were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, stomatitis, weight loss, thrombocytopenia, mucosal inflammation, nasopharyngitis, dysgeusia, and myalgia.[Ref]
Very common (10% or more): Neutropenia (up to 78%), leukopenia (up to 52%), anemia (up to 36%), febrile neutropenia (up to 23%), thrombocytopenia (16%), leukopenia (10.5%)Frequency not reported: Hypoprothrombinemia[Ref]
Very common (10% or more): LVEF decrease (up to 44.3%), congestive heart failure (up to 28%), tachycardia (up to 10%), blood pressure decreased, blood pressure increased, heart beat irregular, palpitation, cardiac flutter, ejection fraction decreased, lymphedema, hot flushCommon (1% to 10%): Asymptomatic cardiac dysfunction, hypertension, thrombotic adverse event, palpitations, cardiac arrhythmias, supraventricular tachyarrhythmia, cardiomyopathy, hypotension, vasodilationUncommon (0.1% to 1%): Cardiac failure, cardiac disorder, ventricular dysfunction, pericardial effusionFrequency not reported: Cardiogenic shock, pericarditis, bradycardia, gallop rhythm present, S3 gallop[Ref]
Very common (10% or more): Infusion-related reactions (up to 54%)Common (1% to 10%): Hypersensitivity, allergic reaction Frequency not reported: Anaphylactic reaction, anaphylactic shock[Ref]
Very common (10% or more): Cough increased (up to 43%), dyspnea (up to 42%), rhinitis (up to 22%), Grade 2 to 5 pulmonary toxicity (14.3%), wheezing, epistaxis, rhinorrhea, oropharyngeal pain, coughCommon (1% to 10%): Upper respiratory infection, rhinitis, pharyngolaryngeal pain, asthma, lung disorder, pleural effusion Uncommon (0.1% to 1%): Pneumonitis, pulmonary infiltrates, pulmonary hypertension, interstitial pneumonitisFrequency not reported: Pulmonary insufficiency, pulmonary fibrosis, respiratory distress, respiratory failure, lung infiltration, acute pulmonary edema, acute respiratory distress syndrome, bronchospasm, hypoxia, oxygen saturation decreased, laryngeal edema, pulmonary edema, orthopneaPostmarketing reports: Bronchospasm, hypoxia, pleural effusions, non-cardiogenic pulmonary edema[Ref]
Very common (10% or more): Infection (up to 47%), herpes simplex (up to 38%), pharyngitis (up to 30%), sinusitis (up to 21%), upper respiratory tract infections (19%), urinary tract infection (up to 18%), antibody to trastuzumab (the active ingredient contained in Herceptin) (up to 14.6%), nasopharyngitis (13%), flu syndrome (up to 12%)Common (1% to 10%): Nasopharyngitis, influenza, urinary tract infection, neutropenic sepsis, cystitis, herpes zoster, influenza, skin infection, rhinitis, erysipelas, cellulitis, pneumonia, post-operative wound infectionUncommon (0.1% to 1%): Sepsis[Ref]
Postmarketing reports of pathological evidence of glomerulopathy included membranous glomerulonephritis, focal glomerulosclerosis, and fibrillary glomerulonephritis.  Complications included volume overload and congestive heart failure.[Ref]
Very common (10% or more): Renal failure and impairment (18%)Common (1% to 10%): Grade 3 or 4 renal failure, renal disorder, hyperbilirubinemiaFrequency not reported: Glomerulonephritis membranous, glomerulonephropathy, renal failurePostmarketing reports: Nephrotic syndrome with pathological evidence of glomerulopathy[Ref]
Very common (10% or more): Nausea (up to 76%), vomiting (up to 53%), diarrhea (up to 45%), abdominal pain (up to 34%), stomatitis (24%), nausea and vomiting (18%), lip swelling, pancreatitis, constipation, dyspepsiaCommon (1% to 10%): Dysphagia, upper abdominal pain, hemorrhoids, dry mouth[Ref]
Very common (10% or more): Headache (up to 44%), fatigue (35%), insomnia (up to 29%), dizziness (up to 24%), paresthesia (up to 23%), peripheral neuritis (up to 23%), neuropathy (up to 13%), dysgeusia (10%), tremor, hypoesthesiaCommon (1% to 10%): Peripheral neuropathy, hypertonia, somnolence, ataxiaRare (less than 0.1%): ParesisFrequency not reported: Brain edema[Ref]
Very common (10% or more): Rash (up to 38%), nail changes (11.5%), acne (up to 11%), rash/desquamation (10.9%), erythema, swelling face, palmar-plantar erythrodysesthesia syndrome, nail disorder, alopecia, nail toxicityCommon (1% to 10%): Pruritus, dry skin, ecchymosis, hyperhidrosis, maculopapular rash, onychoclasis, dermatitis, contusionUncommon (0.1% to 1%): UrticariaFrequency not reported: Angioedema[Ref]
Very common (10% or more): Arthralgia (up to 37%), back pain (up to 34%), bone pain (up to 24%), muscle tightness, myalgia Common (1% to 10%): Muscle spasm, neck pain, pain in extremity, arthritis[Ref]
Very common (10% or more): Anorexia (up to 31%) hypokalemia (28%), weight decrease (23%), weight increased, decreased appetiteFrequency not reported: HyperkalemiaPostmarketing reports: Volume overload[Ref]
Very common (10% or more): Asthenia (up to 62%), pain (up to 61%), fever (up to 56%), chills (up to 41%), peripheral edema (up to 22%), hot flashes (17.1%), accidental injury (up to 13%), mucosal inflammation (13%), edema (11%), chest pain, influenza-like symptomsCommon (1% to 10%): Edema peripheral, asthenia, malaiseUncommon (0.1% to 1%): DeafnessRare (less than 0.1%): Sudden death[Ref]
Common (1% to 10%): Hepatocellular injury, hepatitis, liver tendernessRare (less than 0.1%): JaundiceFrequency not reported: Hepatic failure[Ref]
Very common (10% or more): Conjunctivitis, lacrimation increasedCommon (1% to 10%): Dry eyeFrequency not reported: Papilledema, retinal hemorrhage[Ref]
Oligohydramnios sequence included pulmonary hypoplasia, skeletal abnormalities, and neonatal death.[Ref]
Common (1% to 10%): Breast inflammation/mastitisPostmarketing reports: Oligohydramnios or oligohydramnios sequence[Ref]
Very common (10% or more): Depression (up to 20%), insomniaCommon (1% to 10%): Anxiety, thinking abnormal[Ref]
Uncommon (0.1% to 1%): Autoimmune thyroiditis[Ref]
Frequency not reported: Malignant neoplasm progression, neoplasm progression[Ref]
1. Cerner Multum,  Inc. "Australian Product Information." O 0
2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
3. "Product Information. Herceptin (trastuzumab)." Genentech, South San Francisco, CA. 
4. Cathomas R,  Goldhirsch A,  von Moos R "Drug-induced immune thrombocytopenia." N Engl J Med 357 (2007): 1870-1; author reply 1871
5. Perez EA,  Rodeheffer R "Clinical cardiac tolerability of trastuzumab." J Clin Oncol 22 (2004): 322-9
6. Keefe DL "Trastuzumab-associated cardiotoxicity." Cancer 95 (2002): 1592-600
7. Seidman A,  Hudis C,  Pierri MK, et al. "Cardiac dysfunction in the trastuzumab clinical trials experience." J Clin Oncol 20 (2002): 1215-21
8. Behr TM,  Behe M,  Wormann B "Trastuzumab and breast cancer." N Engl J Med 345 (2001): 995-6
9. Pansegrau GK,  Grant DR,  Norris B,  Gelmon KA "Trastuzumab-associated peripheral vascular toxicity." J Clin Oncol 25 (2007): 1438-40
10. Srinivasan S,  Parsa V,  Liu CY,  Fontana JA "Trastuzumab-induced hepatotoxicity." Ann Pharmacother 42 (2008): 1497-501
11. Montagna E,  Cancello G,  D'Agostino D, et al. "Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab." Cancer Chemother Pharmacol 63 (2008): 275-80
Not all side effects for Herceptin may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Dizziness
fever or chills
headache
muscle aches
nausea or vomiting
shortness of breath
skin rash
sore throat
stuffy or runny nose
unusual tiredness or weakness


Bloody nose
cough
diarrhea
difficult or labored breathing
ear congestion or pain
fast or irregular heartbeat
general feeling of discomfort or illness
head congestion
hoarseness or other voice changes
increased cough
joint pain
loss of appetite
nasal congestion
pain or tenderness around the eyes and cheekbones
shivering
sneezing
sweating
swelling of the feet or lower legs
tightness in the chest
trouble with sleeping
vomiting


Blue lips and fingernails
blurred vision
chest pain
confusion
cough or hoarseness, accompanied by fever or chills
faintness or lightheadedness when getting up suddenly from a lying or sitting position suddenly
itching
large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, feet, or sex organs
lower back or side pain, accompanied by fever or chills
painful or difficult urination, accompanied by fever or chills
pale skin
redness of the skin
trouble with breathing


Black, tarry stools
bloody or cloudy urine
sores, ulcers, or white spots in the mouth
unusual bleeding or bruising
weight gain


Pain


Numbness or tingling of the hands or feet

